You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
白雲山(00874.HK):分公司收到藥品註冊證書
格隆匯 04-13 22:05

格隆匯 4 月 13日丨白雲山(00874.HK)公佈,分公司廣州白雲山醫藥集團股份有限公司白雲山製藥總廠("白雲山製藥總廠")於2021年4月12日收到國家藥品監督管理局核准簽發的注射用頭孢西丁鈉1.0g、0.5g的《藥品註冊證書》(證書編號:2021S00315,2021S00316)。

頭孢西丁鈉是第二代頭孢菌素類,對革蘭陰性菌有較強的抗菌作用。臨牀主要用於敏感菌所致的呼吸道感染、泌尿道感染、腹膜炎、盆腔內感染、敗血症(包括傷寒)、婦科感染、骨關節軟組織感染、心內膜炎等。由於本品對厭氧菌有效及對β-內酰胺酶穩定,故特別適用需氧及厭氧菌混合感染,以及對於產β-內酰胺酶且對本品敏感細菌引起的感染。屬於中國國家醫保目錄(2020版)乙類用藥。

2013年6月,白雲山製藥總廠向國家食品藥品監督管理局遞交藥品註冊申請獲受理。經查詢,目前國內注射用頭孢西丁鈉的主要生產廠家為揚子江藥業集團有限公司、國藥致君(深圳)製藥有限公司、深圳信立泰藥業股份有限公司等企業。根據米內網數據,2019年城市、縣級公立醫院的注射用頭孢西丁鈉銷售額為人民幣38.14億元。截至目前,白雲山製藥總廠在注射用頭孢西丁鈉研發項目上已投入研發費用合計約人民幣576.96萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account